Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

by Tetsu Hayashida, Hiromitsu Jinno, Katsuaki Mori, Hiroki Sato, Akira Matsui, Takashi Sakurai, Hiroaki Hattori, Shin Takayama, Masahiro Wada, Maiko Takahashi, Hirohito Seki, Tomoko Seki, Aiko Nagayama, Akiko Matsumoto, Yuko Kitagawa
Published 2018-06-01

Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?

by Eric Thebault, Sophie Piperno-Neumann, Diep Tran, Hélène Pacquement, Perrine Marec-Berard, Cyril Lervat, Marie-Pierre Castex, Morgane Cleirec, Emmanuelle Bompas, Jean-Pierre Vannier, Dominique Plantaz, Laure Saumet, Cecile Verite, Olivier Collard, Claire Pluchart, Claire Briandet, Laure Monard, Laurence Brugieres, Marie-Cécile Le Deley, Nathalie Gaspar
Published 2021-04-01

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients

by Pin Zhang, Zhongsheng Tong, Fuguo Tian, Yongsheng Wang, Junlan Yang, Weilian Li, Lijun Di, Wei Liu, Li Tang, Rongguo Qiu, Binghe Xu
Published 2016-08-01

Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial

by Nils Venhoff, Wolfgang A. Schmidt, Peter Lamprecht, Hans-Peter Tony, Christine App, Christian Sieder, Carolin Legeler, Claudia Jentzsch, Jens Thiel
Published 2021-08-01

A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19...

by Paolo Chiodini, Laura Arenare, Maria Carmela Piccirillo, Francesco Perrone, Ciro Gallo
Published 2020-12-01

Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial

by Guckenberger Matthias, Hawkins Maria, Flentje Michael, Sweeney Reinhart A
Published 2012-11-01

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial

by Alice Markussen, Lars Henrik Jensen, Laura Vittrup Diness, Finn Ole Larsen
Published 2020-07-01

A single-blinded, randomized, parallel group superiority trial investigating the effects of footwear and custom foot orthoses versus footwear alone in individuals with patellofemor...

by Narelle Wyndow, Kay M. Crossley, Bill Vicenzino, Kylie Tucker, Natalie J. Collins
Published 2017-04-01

Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress

by Yaning Wang, Wanqi Chen, Yixin Shi, Chengrui Yan, Ziren Kong, Yuekun Wang, Yu Wang, Wenbin Ma
Published 2021-09-01

Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma

by Yevette McGovern, Charlie D. Zhou, Robin L. Jones
Published 2017-11-01

Multicenter randomized phase II trial of prophylactic right‐half dissection of superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic head cancer

by Suguru Yamada, Sohei Satoi, Hideki Takami, Tomohisa Yamamoto, Isaku Yoshioka, Fuminori Sonohara, So Yamaki, Kazuto Shibuya, Masamichi Hayashi, Daisuke Hashimoto, Masahiko Ando, Kenta Murotani, Mitsugu Sekimoto, Yasuhiro Kodera, Tsutomu Fujii
Published 2021-01-01

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)

by Tito R. Mendoza, Loretta A. Williams, Karen N. Keating, Jonathan Siegel, Cem Elbi, Anna K. Nowak, Raffit Hassan, Brian Cuffel, Charles S. Cleeland
Published 2019-06-01

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 stu...

by Christos Chouaid, Hervé Le, Chrystelle Locher, Cecile Dujon, Pascal Thomas, Jean Bernard Auliac, Isabelle Monnet, Alain Vergnenegre
Published 2012-07-01

Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials

by Goffin John R, Pond Greg R
Published 2011-12-01

Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

by Yun Leng, Lugui Qiu, Jian Hou, Yaozhong Zhao, Xuejun Zhang, Shifang Yang, Hao Xi, Zhongxia Huang, Ling Pan, Wenming Chen
Published 2016-09-01

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

by Christine Chevreau, Christophe Massard, Aude Flechon, Rémy Delva, Gwenaëlle Gravis, Jean‐Pierre Lotz, Jacques‐Olivier Bay, Marine Gross‐Goupil, Karim Fizazi, Loïc Mourey, Angelo Paci, Jérôme Guitton, Fabienne Thomas, Bénédicte Lelièvre, Joseph Ciccolini, Sotheara Moeung, Yohan Gallois, Pascale Olivier, Stéphane Culine, Thomas Filleron, Etienne Chatelut
Published 2021-04-01

PORTAF – postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation – study protocol for a randomized controlled trial

by R. Bütof, M. Simon, S. Löck, E. G. C. Troost, S. Appold, M. Krause, M. Baumann
Published 2017-12-01

A PREDICTIVE PROBABILITY INTERIM DESIGN FOR PHASE II CLINICAL TRIALS WITH CONTINUOUS ENDPOINTS

by Liu, Meng
Published 2017

Accelerated partial breast irradiation with 3-dimensional conformal and image-guided intensity-modulated radiotherapy following breast conserving surgery – 7-Year results of a phas...

by Norbert Mészáros, Tibor Major, Gábor Stelczer, Levente Jánváry, Zoltán Zaka, Dávid Pukancsik, Zoltán Takácsi-Nagy, János Fodor Md, Csaba Polgár
Published 2020-12-01